Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,309.43

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,944.53 10
Food and Beverage $364.90 6

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $4,191.76 15
PFIZER INC. $117.67 1

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $4,309.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $117.6706/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672262367 CMS
Eli Lilly and Company $590.7605/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686397 CMS
Eli Lilly and Company $79.9705/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689841 CMS
Eli Lilly and Company $171.1305/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689843 CMS
Eli Lilly and Company $14.9805/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693327 CMS
Eli Lilly and Company $110.3804/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700187 CMS
Eli Lilly and Company $74.9204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682831 CMS
Eli Lilly and Company $343.3304/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682833 CMS
Eli Lilly and Company $116.8204/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682835 CMS
Eli Lilly and Company $1,131.2004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686395 CMS
Eli Lilly and Company $252.4604/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689839 CMS
Eli Lilly and Company $45.9404/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693323 CMS
Eli Lilly and Company $21.9904/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693325 CMS
Eli Lilly and Company $31.4204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657696735 CMS
Eli Lilly and Company $1,029.9604/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700183 CMS
Eli Lilly and Company $176.5004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $479.27 12/31/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 1042488239
Principal investigator 1 Merck Sharp & Dohme LLC $161,320.80 12/31/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 1042564115
Principal investigator 1 Merck Sharp & Dohme LLC $78,100.00 12/28/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042569717
Principal investigator 1 BioNTech SE $869.55 12/19/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317653
Principal investigator 1 Merck Sharp & Dohme LLC $291,100.00 12/19/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Dose Escalation,Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies No dispute reported 06/30/2026 1042489329
Principal investigator 1 Merck Sharp & Dohme LLC $75,220.00 12/13/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A multicentre, open-label, non-randomized, phase 1a,1b study of NG 350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours FORTIFY No dispute reported 06/30/2026 1042489643
Principal investigator 1 BioNTech SE $869.55 12/12/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317647
Principal investigator 1 Servier BioInnovation $11,940.17 12/11/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367783
Principal investigator 1 SANOFI US SERVICES INC. $70,937.00 12/08/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036008215
Principal investigator 1 BioNTech SE $12,921.70 11/21/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317655
Principal investigator 1 BioNTech SE $808.35 11/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317649
Principal investigator 1 Merck Sharp & Dohme LLC $42,600.00 11/09/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042569533
Principal investigator 1 SANOFI US SERVICES INC. $675.50 11/08/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036008207
Principal investigator 1 SANOFI US SERVICES INC. $109,638.94 11/08/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036008229
Principal investigator 1 BioNTech SE $2,036.60 11/07/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317643
Principal investigator 1 PFIZER INC. $364,207.73 11/04/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046390887
Principal investigator 1 BioNTech SE $19,221.90 10/25/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317657
Principal investigator 1 BioNTech SE $2,316.07 10/19/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317873
Principal investigator 1 BioNTech SE $1,190.85 10/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317651
Principal investigator 1 BioNTech SE $5,446.80 10/10/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317645
Principal investigator 1 Incyte Corporation $313.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677349
Principal investigator 1 Incyte Corporation $3,283.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677369
Principal investigator 1 Incyte Corporation $23,807.82 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677385
Principal investigator 1 Incyte Corporation $975.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677401
Principal investigator 1 Incyte Corporation $3,750.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677417
Principal investigator 1 Incyte Corporation $2,769.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677433
Principal investigator 1 Incyte Corporation $4,689.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677449
Principal investigator 1 Incyte Corporation $1,049.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677465
Principal investigator 1 Incyte Corporation $5,922.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677481
Principal investigator 1 Incyte Corporation $3,098.30 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677497
Principal investigator 1 Incyte Corporation $1,575.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677513
Principal investigator 1 Incyte Corporation $6,250.00 10/04/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040677529
Principal investigator 1 BioNTech SE $22,665.25 10/03/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317641
Principal investigator 1 Servier BioInnovation $532.71 09/26/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367743
Principal investigator 1 Servier BioInnovation $2,130.84 09/26/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367757
Principal investigator 1 BioNTech SE $579.70 09/21/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060313313
Principal investigator 1 BioNTech SE $289.85 09/21/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060313315
Principal investigator 1 Merck KGaA $3,502.80 09/07/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 1051334195
Principal investigator 1 SANOFI US SERVICES INC. $232,487.75 08/18/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036007579
Principal investigator 1 Eli Lilly and Company $166,157.32 08/16/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1038064507
Principal investigator 1 BioNTech SE $2,318.80 08/10/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060314179
Principal investigator 1 BioNTech SE $17,010.34 08/03/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060314819
Principal investigator 1 BioNTech SE $17,010.34 08/03/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317949
Principal investigator 1 Servier BioInnovation $3,766.05 07/27/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367797
Principal investigator 1 BioNTech SE $8,327.45 07/18/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316471
Principal investigator 1 Merck KGaA $125,308.80 07/13/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 1051334193
Principal investigator 1 BioNTech SE $1,291.15 07/11/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060314185
Principal investigator 1 PFIZER INC. $14,406.25 07/08/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046486407
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $99.00 06/30/2023 Non-covered Recipient Entity
University Of Texas Md Anderson Cancer Center-Investigational Cancer Therapeutics
Phase I/IIA FIH CCR8 Mono/Combo - A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1027457633
Principal investigator 1 BioNTech SE $3,541.10 06/28/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316087
Principal investigator 1 PFIZER INC. $37,500.00 06/27/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I II STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AVELUMAB IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES WI2163822 No dispute reported 06/30/2026 1046533267
Principal investigator 1 PFIZER INC. $150,000.00 06/23/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I II STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AVELUMAB IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES WI2163822 No dispute reported 06/30/2026 1046507749
Principal investigator 1 PFIZER INC. $112,500.00 06/23/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE I II STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AVELUMAB IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES WI2163822 No dispute reported 06/30/2026 1046518687
Principal investigator 1 Incyte Corporation $2,143.00 06/22/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors No dispute reported 06/30/2026 1040675599
Principal investigator 1 BioNTech SE $6,453.20 06/20/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316075
Principal investigator 1 BioNTech SE $8,205.90 06/13/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316063
Principal investigator 1 SANOFI US SERVICES INC. $59,410.00 05/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036007535
Principal investigator 1 SANOFI US SERVICES INC. $3,900.00 05/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036007545
Principal investigator 1 SANOFI US SERVICES INC. $32.50 05/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036007555
Principal investigator 1 BioNTech SE $39,979.75 05/16/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316069
Principal investigator 1 PFIZER INC. $3,682.85 05/16/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046522537
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $240,979.18 05/11/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors No dispute reported 06/30/2026 1027439423
Principal investigator 1 BioNTech SE $23,355.45 05/09/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316049
Principal investigator 1 BioNTech SE $30,948.50 05/03/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316043
Principal investigator 1 SANOFI US SERVICES INC. $29,743.13 05/03/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1036007567
Principal investigator 1 Incyte Corporation $141,970.90 04/28/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1040675381
Principal investigator 1 Incyte Corporation $1,382.80 04/28/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1040675397
Principal investigator 1 Merck KGaA $126,606.60 04/27/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 1051334187
Principal investigator 1 BioNTech SE $11,188.55 04/26/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316081
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,340.24 04/25/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A phase I through Ib and or II open label multicenter study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies No dispute reported 06/30/2026 1017227917
Principal investigator 1 PFIZER INC. $1,794.82 04/25/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046435949
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,563.48 04/20/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Open label multicenter Phase l and or ll study of the safety and efficacy of PDR001 administered to patients with advanced malignancies No dispute reported 06/30/2026 1017229865
Principal investigator 1 BioNTech SE $25,500.00 04/13/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316055
Principal investigator 1 Merck KGaA $89,199.00 04/06/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors No dispute reported 06/30/2026 1051334191
Principal investigator 1 PFIZER INC. $859.91 03/31/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046447828
Principal investigator 1 BioNTech SE $1,449.25 03/29/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316193
Principal investigator 1 BioNTech SE $6,466.29 03/29/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060317929
Principal investigator 1 PFIZER INC. $934.91 03/25/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046453783
Principal investigator 1 Servier BioInnovation $37,024.39 03/16/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367771
Principal investigator 1 Merck Sharp & Dohme LLC $17,750.00 03/14/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First-in-Human Phase I Study of NL-201 in Patients With Relapsed or Refractory Cancer No dispute reported 06/30/2026 1042489553
Principal investigator 1 Merck Sharp & Dohme LLC $179,659.27 03/08/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 1042564124
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,828.77 03/01/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A phase I and or II open label multi center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors No dispute reported 06/30/2026 1017227913
Principal investigator 1 BioNTech SE $2,834.75 02/28/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060318871
Principal investigator 1 Genentech, Inc. $14,662.05 02/24/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
CD25 combination study with atezo No dispute reported 06/30/2026 1040217825
Principal investigator 1 PFIZER INC. $1,794.82 02/24/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046457523
Principal investigator 1 Genentech, Inc. $57,562.50 02/21/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
CD25 combination study with atezo No dispute reported 06/30/2026 1040217813
Principal investigator 1 BioNTech SE $6,482.95 02/16/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316113
Principal investigator 1 BioNTech SE $2,834.75 02/09/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316145
Principal investigator 1 Servier BioInnovation $1,404.76 02/07/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367809
Principal investigator 1 Servier BioInnovation $351.19 02/07/2023 Non-covered Recipient Entity
University of Texas, MD Anderson
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1056367821
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $831,084.00 02/06/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/IIA DGK FIH Mono / Combo in Solid Tumors - CA099-003 - A Phase I/II Study of BMS-986408 Alone and In Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1027439463
Principal investigator 1 BioNTech SE $19,124.15 02/02/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316119
Principal investigator 1 BioNTech SE $3,541.10 01/25/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Pre-commercial No dispute reported 06/30/2026 1060316133
Principal investigator 1 PFIZER INC. $859.91 01/24/2023 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046539757
Principal investigator 1 Merck Sharp & Dohme LLC $32,500.00 01/17/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A multicentre, open-label, non-randomized, phase 1a,1b study of NG 350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours FORTIFY No dispute reported 06/30/2026 1042489641
Principal investigator 1 Incyte Corporation $758.70 01/09/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1040674559
Principal investigator 1 Karyopharm Therapeutics Inc. $375,000.00 01/06/2023 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies No dispute reported 06/30/2026 1051824597